Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trisha R Berger

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Nature Communications|November 2, 2025
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical modelsFilippo Birocchi, Antonio J Almazan, Aiyana Parker, et al.
Blood Cancer Discovery|January 11, 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesStefanie R Bailey, Sonika Vatsa, Rebecca C Larson, et al.
Nature Communications|November 18, 2023
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myelomaRebecca C Larson, Michael C Kann, Charlotte Graham, et al.
Science Translational Medicine|June 5, 2024
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimeticsFelix Korell, Michael L Olson, Diego Salas-Benito, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a timeDiego Salas-Benito, Filippo Birocchi, Sangwoo Park, et al.
Blood|November 21, 2024
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLHarrison J Silva, Grace Martin, Filippo Birocchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
An In Vivo Model of Human Macrophages in Metastatic MelanomaValentin Voillet, Trisha R Berger, Kelly M McKenna, et al.
Nature|April 14, 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursRebecca C Larson, Michael C Kann, Stefanie R Bailey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2020
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-SeqAngela C Boroughs, Rebecca C Larson, Nemanja D Marjanovic, et al.
Science Translational Medicine|June 4, 2025
IFN-γ-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor modelsStefanie R Bailey, Hana N Takei, Giulia Escobar, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Nature Communications|November 2, 2025
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical modelsFilippo Birocchi, Antonio J Almazan, Aiyana Parker, et al.
Blood Cancer Discovery|January 11, 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesStefanie R Bailey, Sonika Vatsa, Rebecca C Larson, et al.
Nature Communications|November 18, 2023
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myelomaRebecca C Larson, Michael C Kann, Charlotte Graham, et al.
Science Translational Medicine|June 5, 2024
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimeticsFelix Korell, Michael L Olson, Diego Salas-Benito, et al.
Journal for Immunotherapy of Cancer|September 10, 2025
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a timeDiego Salas-Benito, Filippo Birocchi, Sangwoo Park, et al.
Blood|November 21, 2024
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLHarrison J Silva, Grace Martin, Filippo Birocchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
An In Vivo Model of Human Macrophages in Metastatic MelanomaValentin Voillet, Trisha R Berger, Kelly M McKenna, et al.
Nature|April 14, 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursRebecca C Larson, Michael C Kann, Stefanie R Bailey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2020
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-SeqAngela C Boroughs, Rebecca C Larson, Nemanja D Marjanovic, et al.
Science Translational Medicine|June 4, 2025
IFN-γ-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor modelsStefanie R Bailey, Hana N Takei, Giulia Escobar, et al.
Pageof 3